Latecomer psoriasis treatment 'Bimzelx' launches

By Whang, byung-woo | translator Hong, Ji Yeon

24.11.22 05:33:57

가나다라 0

Offers a benefit of a different inhibitory mechanism for interleukin-17A and 17F compared to existing psoriasis treatments

Higher PASI100 score compared to existing biological agents such as Stelara and Cosentyx

UCB Korea is proceeding with obtaining reimbursement…aims to list the drug for reimbursement by July 2025

UCV Korea has launched Bimzelx (ingredient: bimekizumab) for treating psoriasis and is set to challenge the market.

Although existing psoriasis treatments have taken a share of the market, the company will target unmet needs based on the drug's new mechanism.

▲Ki Heon Jeong, Professor of the Department of Dermatology at Kyung Hee University Medical Center

UCB Korea held a media session on November 20 to celebrate the launch of Bimzelx in South Korea and presented the product's competitiveness in the market.

Bimzelx is the first treatment for plaque psoriasis that bi-specifically inhibits interleukin-17A and 17F (IL-17A, IL-17F). It received the Ministry of Food and Drug Safety (MFDS) approval at the end of August.

IL-17A and IL-17F are cytokines that pl

Whang, byung-woo(tuai@dailypharm.com)

If you want to see the full article, please JOIN US (click)